Xiaoli Xie

Dr. Xiaoli Xie

Laboratory of Molecular Genetics of Aging and Tumor, Kunming University of Science and Technology, Kunming, Yunnan, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Genes
Verified
Journal Article
Open access
PDF file
HLHao Li
Hao Li
LQLei Qiu
Lei Qiu
QLQing Liu
Qing Liu
ZMZelong Ma
Zelong Ma
XXXiaoli Xie
Xiaoli Xie
XWXiaoming Wu
Xiaoming Wu
Aging has been recently reported to promote lung cancer initiation and progression. Senescent fibroblasts gain a cancer-associated fibroblast (CAF) phenotype, and exert a powerful influence on cancer behavior, such as tumor cell growth and metastasis. However, mechanisms linking fibroblast senescence with CAF activation remain poorly understood. Our study shows that senescent fibroblasts displayed CAF properties, including the highly expressed CAF markers, α-SMA and Vimentin, and CAF-specific factors, CXCL12, FGF10, IL6 and COL1A1, which significantly increased collagen contractile activity and promoted the migration and invasion of lung cancer cells, H1299 and A549. We were further able to show that CAF characteristics in senescent fibroblasts could be regulated by the Stat3 pathway. Intracellular ROS accumulation activates the Stat3 pathway during senescence. Thus, our findings indicate that senescent fibroblasts mediate a CAF function with the Stat3 pathway. We further propose a novel Stat3 dependent targetable mechanism, which is instrumental in mediating the migration and invasion of lung cancer cells.

26 June 2025 in Translational Oncology
Verified
Journal Article
Open access
QQQi Qi
Qi Qi
WYWenhao Yang
Wenhao Yang
LLLiang Li
Liang Li
YTYuheng Tang
Yuheng Tang
YCYongzhi Chen
Yongzhi Chen
XXXiaoli Xie
Xiaoli Xie
• A novel macrophage differentiation-based classifier (MMDCSS) accurately predicts prognosis in TNBC patients. • Repurposing finasteride to modulate ZBTB20 offers a clinically viable strategy to reverse immunosuppression and improve TNBC therapy.